ArticleLaryngoscope investigative otolaryngology2022
Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III-V thyroid nodules.
Article in Laryngoscope investigative otolaryngology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Integration of AI-driven ultrasound and molecular testing to improve diagnosis of indeterminate thyroid nodules.Frontiers in endocrinology · 2026Pooled it
- Sociodemographic and clinical predictors of malignancy in thyroid nodules: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- The Value of Multimodal Ultrasound in Differentiating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.Cancers · 2026Article
- Comparing the diagnostic accuracy of pre-operative genetic testing for thyroid cancer on fine needle aspiration cytology specimens: a systematic review and meta-analysis of diagnostic accuracy.Discover oncology · 2025Article
- In suspicious for malignancy thyroid nodule aspirates, nuclei characteristics deserves special attention in reported cytology analysis - real world scenario cohort.Archives of endocrinology and metabolism · 2025Article
- Ultrasound radiomics models improve preoperative diagnosis and reduce unnecessary biopsies in indeterminate thyroid nodules.Frontiers in endocrinology · 2025Article
- Application and limitations of ultrasound for the early diagnosis of thyroid cancer: a systematic review and meta-analysis.American journal of translational research · 2025Article
- Ultrasound radiomics and genomics improve the diagnosis of cytologically indeterminate thyroid nodules.Frontiers in endocrinology · 2025Review
- Impact of ultrasound elastography in evaluating Bethesda category IV thyroid nodules with histopathological correlation.Frontiers in endocrinology · 2024Article
- Managing Bethesda IV thyroid nodules in an iodine-deficient population.Gland surgery · 2023Article
- Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III-V thyroid nodules.Laryngoscope investigative otolaryngology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the role of patient characteristics, ultrasound findings, and molecular testing in predicting risk of malignancy in Bethesda III, IV, and V thyroid nodules. Design: Single institution retrospective review of 230 patients with Bethesda III, IV, and V cytopathology undergoing thyroidectomy between 2009 and 2018. Setting: Private and public tertiary urban university hospitals at the same academic institution. Subjects and methods: Patients who underwent thyroidectomy with Bethesda III, IV, and V nodules were included. Patient demographics, presence of underlying thyroid disease, nodule size, sonographic features, gene expression results, and surgical procedure were documented. Correlation between these variables and final histopathologic diagnosis of malignancy was analyzed. Results: The 230 patients (103 Bethesda III, 64 Bethesda IV, and 63 Bethesda V) were included for analysis. Bethesda III nodules harbored malignancy in 26.2% of cases compared with 26.6% of Bethesda IV nodules and 82.5% of Bethesda V nodules. On multivariate analysis, age was inversely correlated with a diagnosis of malignancy (OR: 0.98, 95% confidence interval [CI]: 0.96-0.99, Conclusions: The presence of microcalcifications in thyroid nodules categorized as Bethesda III-V is an independent risk factor for malignancy. The combination of microcalcifications, irregular margins, and hypoechogenicity is associated with a greater malignancy risk in nodules indeterminate for thyroid cancer on cytopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.